source stringlengths 2 222 | date stringlengths 19 19 | url stringlengths 22 853 ⌀ | text stringlengths 0 10k ⌀ | title stringlengths 0 701 | context_id stringlengths 1 9 | document_id stringclasses 2
values | document_type stringclasses 2
values |
|---|---|---|---|---|---|---|---|
InvestorPlace | 2023-07-20 16:18:18 | https://investorplace.com/2023/07/3-of-the-best-dividend-stocks-to-buy-for-passive-income-growth/ | Investors seeking income from dividend stocks should carefully consider the yield offered. While the average yield in the S&P 500 is 1.56%, some stocks offer double or even triple that amount. | 3 of the Best Dividend Stocks to Buy for Passive Income Growth | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2023-07-20 12:49:18 | https://investorplace.com/2023/07/7-fantastic-forever-stocks-for-long-term-lucrative-gains/ | Investing is about building a stable long-term portfolio, not just seeking immediate gains. In a mixed economic climate with rising employment figures, savvy investors seek forever stocks. | 7 Fantastic Forever Stocks for Long-Term Lucrative Gains | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2023-07-19 10:00:00 | https://seekingalpha.com/article/4617891-abbvie-dancing-on-humiras-grave | AbbVie's flagship drug Humira is facing competition from biosimilars, but the company is expected to offset revenue losses in the segment with Skyrizi & Rinvoq. Two real growth drivers for AbbVie are Oncology and Neuroscience segments. Oncology and neuroscience should grow through 2030 with CAGRs of 11.38% and 10.79%, ... | AbbVie: Dancing On Humira's Grave | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
MarketBeat | 2023-07-17 07:31:07 | https://www.marketbeat.com/originals/3-dividend-stocks-that-still-make-sense-in-2023/?utm_source=snapi | It was hard to find big stock market winners in 2022. But dividend stocks were among the better performers. | 3 Dividend Stocks That Still Make Sense in 2023 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2023-07-13 10:51:21 | https://seekingalpha.com/article/4616848-fdl-underperforming-in-2023 | FDL: Underperforming In 2023 | FDL: Underperforming In 2023 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2023-07-12 17:33:58 | https://investorplace.com/2023/07/3-biotech-stocks-to-sell-before-they-damage-your-portfolio/ | There are several reasons that investors should be cautious about buying or holding biotech stocks at this point. First, the Street is generally bearish on the sector lately. | 3 Biotech Stocks to Sell Before They Damage Your Portfolio | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Market Watch | 2023-07-12 15:59:00 | https://www.marketwatch.com/story/drugmakers-deal-making-will-plow-ahead-despite-antitrust-scrutiny-analysts-say-eb36f41b | The brisk pace of biopharmaceutical deal making seen in the first half of this year may only accelerate in the months ahead, even as regulators take a hard look at some of the bigger deals, analysts say. | Drugmakers' deal making will plow ahead despite antitrust scrutiny, analysts say | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2023-07-11 19:39:34 | https://seekingalpha.com/article/4616437-4-dividend-aristocrat-buys-for-july-and-6-to-watch | "Dividend Aristocrats in the S&P 500 Index have raised their annual payouts every year for at least 25 consecutive years. "--Kiplinger.com/Investing. 67 Aristocrats, screened as of July 7, 2023, represented all eleven Morningstar Sectors. Broker-estimated top ten net-gains ranged 20.58%-43.58%, topped-by TGT & VFC. By ... | 4 Dividend Aristocrat Buys For July And 6 To Watch | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2023-07-11 07:15:00 | https://seekingalpha.com/article/4616157-the-ultimate-buffett-style-5-percent-yielding-dividend-aristocrat-portfolio | The economic data is showing that a recession is almost certainly coming, but it now appears to be most likely to start in the first half of 2024. Impatience, and fear of missing out, have caused many investors to forget the painful lessons of 2022, chasing momentum despite insane valuations in some stocks. Wall Street... | The Ultimate Buffett-Style 5% Yielding Dividend Aristocrat Portfolio | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GuruFocus | 2023-07-10 10:51:35 | https://www.gurufocus.com/news/2036521/abbvies-rd-pipeline-driving-longterm-growth | AbbVie Inc. ( ABBV , Financial) is facing aggressive competition against its blockbuster Humira, which has put pressure on its stock. But with a robust research and development pipeline boasting over 90 compounds and devices, AbbVie still holds promising prospects for long-term growth in my view. | AbbVie's R&D Pipeline: Driving Long-Term Growth | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-07-08 06:14:00 | https://www.fool.com/investing/2023/07/08/3-no-brainer-stocks-you-can-buy-right-now/ | Some investors are fearful about AbbVie right now, but it's better to be greedy with the stock. Pfizer offers a solid dividend and great growth prospects. | 3 No-Brainer Stocks You Can Buy Right Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2023-07-07 11:41:02 | https://investorplace.com/2023/07/the-3-best-dividend-stocks-to-buy-in-july/ | Dividend stocks continue to be highly sought after, especially among investors who seek to generate income. Retirees appreciate the regular payments provided by stocks that offer dividends to their shareholders. | The 3 Best Dividend Stocks to Buy in July | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Schaeffers Research | 2023-07-07 10:41:28 | https://www.schaeffersresearch.com/content/bgs/2023/07/07/just-how-hot-have-these-tech-stocks-been | Subscribers to Chart of the Week received this commentary on Sunday, July 2. | Just How Hot Have These Tech Stocks Been? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-07-07 09:45:00 | https://www.fool.com/investing/2023/07/07/2-struggling-dividend-growth-stocks-could-make/ | AbbVie should survive the loss of exclusivity of its crown jewel, Humira. Amgen's struggles are real, but so is the company's ability to innovate. | 2 Struggling Dividend Growth Stocks That Could Make You Richer | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2023-07-07 09:23:08 | https://www.zacks.com/stock/news/2118019/buy-5-high-roe-stocks-as-market-rally-skids-on-adp-jobs-data | Dillard's (DDS), Suzano (SUZ), Atkore (ATKR), Nexstar (NXST) and AbbVie (ABBV) are some of the stocks with high ROE to profit from as markets decline on better-than-expected ADP jobs data. | Buy 5 High ROE Stocks as Market Rally Skids on ADP Jobs Data | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-07-07 07:15:00 | https://www.fool.com/investing/2023/07/07/dividend-stocks-should-be-part-of-your-retirement/ | If you worry you won't have enough saved up by retirement, dividend stocks can help boost your income. Allocating part of your retirement savings to such equities can reduce depletion of your savings. | Why Dividend Stocks Should Be a Key Part of Your Retirement Plan | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2023-07-06 15:36:39 | https://investorplace.com/2023/07/the-7-best-long-term-stocks-to-buy-in-july/ | Investing features many similarities to the game of baseball, which helps drive the case for the best long-term stocks in July. Unlike the NFL where teams play only 17 regular-season games, in MLB, there are 876 – no, excuse me, 162 games. | The 7 Best Long-Term Stocks to Buy in July | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-07-06 13:32:00 | https://www.fool.com/investing/2023/07/06/is-abbvies-dividend-yield-safe/ | AbbVie is a top-shelf dividend stock. However, the company's free cash flows are set to decline this year in response to biosimilar competition. | Is AbbVie's Dividend Yield Safe? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-07-06 09:45:00 | https://www.fool.com/investing/2023/07/06/got-5000-these-are-3-of-the-best-stocks-to-buy-in/ | AbbVie is a heavily discounted healthcare stock whose business is in fine shape. Verizon offers a mouthwatering dividend at a very manageable payout ratio. | Got $5,000? These Are 3 of the Best Stocks to Buy in July | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2023-07-06 08:00:00 | https://seekingalpha.com/article/4615441-abbvie-use-this-buying-opportunity-rating-upgrade | AbbVie stock has been upgraded to a buy again due to its attractive yield and less demanding valuation, despite expectations of a down year in 2023. The healthcare company is seen as a resilient investment choice in uncertain economic times, offering a 4.4% dividend yield and a low beta of 0.54. Despite a decline in sa... | AbbVie: Use This Buying Opportunity (Rating Upgrade) | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2023-07-05 15:16:12 | https://investorplace.com/2023/07/the-7-best-forever-stocks-to-buy-for-july-2023/ | With the latest encouraging read on inflation sending the market on a high to end the first half of this year, the idea of acquiring the best forever stocks may seem overly cautious. After all, with sentiment strong on apparently justifiable reasons, investors may be better served with risk-on securities. | The 7 Best Forever Stocks to Buy for July 2023 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Proactive Investors | 2023-07-05 10:14:42 | https://www.proactiveinvestors.com/companies/news/1019859?SNAPI | AbbVie is about to face stiffer competition for its blockbuster rheumatoid arthritis drug Humira from a new biosimilar about to be launched in the US. Celltrion Healthcare, a South Korean company, has introduced Yuflyma, a biosimilar version Humira, in the United States. | AbbVie braces for increased Humira competition from cheaper biosimilar | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Reuters | 2023-07-05 07:34:56 | https://www.reuters.com/business/healthcare-pharmaceuticals/celltrion-launches-biosimilar-abbvies-blockbuster-drug-humira-us-2023-07-05/ | South Korea's Celltrion Healthcare has launched a copycat version to AbbVie Inc's Humira at about a 5% discount, adding to the growing competition for the blockbuster rheumatoid arthritis drug in the U.S. | Celltrion launches biosimilar of AbbVie's blockbuster drug Humira in US | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-07-04 08:14:00 | https://www.fool.com/investing/2023/07/04/3-spectacular-dividend-stocks-to-buy-in-july/ | AbbVie is a Dividend King with a high yield. Bristol Myers Squibb is an underrated bargain. | 3 Spectacular Dividend Stocks to Buy in July | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Reuters | 2023-07-03 13:59:11 | https://www.reuters.com/business/healthcare-pharmaceuticals/indias-biocon-biologics-launches-biosimilar-abbvies-humira-us-2023-07-03/ | India's Biocon Biologics said on Monday it has launched a biosimilar version of AbbVie's blockbuster rheumatoid arthritis drug Humira in the United States. | India's Biocon Biologics launches biosimilar for AbbVie's Humira in US | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Reuters | 2023-07-03 10:59:02 | https://www.reuters.com/business/healthcare-pharmaceuticals/fresenius-launches-biosimilar-version-abbvies-humira-5-discount-2023-07-03/ | The generic drug unit of Germany's Fresenius said on Monday the price for Idacio, its copycat version of Abbvie's top-selling rheumatoid arthritis drug, will be at a 5% discount to Humira's list price. | Fresenius launches biosimilar version of AbbVie's Humira at 5% discount | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-07-03 09:15:00 | https://www.fool.com/investing/2023/07/03/merck-and-abbvie-are-facing-big-patent-cliffs-but/ | Each has a blockbuster therapy that is likely facing declining sales. But both companies' pipelines have more than 100 programs. | Merck and AbbVie Are Facing Big Patent Cliffs, But Here's Why Both Are Still Buys | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Reuters | 2023-07-03 09:12:53 | https://www.reuters.com/business/healthcare-pharmaceuticals/coherus-biosciences-launches-biosimilar-version-abbvies-blockbuster-humira-2023-07-03/ | Coherus BioSciences said on Monday it has launched a copycat version of AbbVie's Humira in the United States at a discount of over 85% to the blockbuster arthritis drug. | Coherus BioSciences launches biosimilar version of AbbVie's blockbuster Humira | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-07-03 05:52:00 | https://www.fool.com/investing/2023/07/03/magnificent-dividend-stocks-to-buy-in-july/ | AbbVie is a Dividend King that's poised to deliver robust long-term growth. Brookfield Renewable should benefit tremendously from the increased demand for clean energy. | 3 Magnificent Dividend Stocks to Buy Hand Over Fist in July | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-07-02 09:30:00 | https://www.fool.com/investing/2023/07/02/could-this-new-drug-be-a-blockbuster-for-these-2/ | In clinical trials, epcoritamab proved highly effective in treating a certain kind of lymphoma. The cancer drug, developed jointly by AbbVie and Genmab, has a huge potential market. | Could This New Drug Be a Blockbuster for These 2 Pharma Collaborators? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Reuters | 2023-07-01 00:20:58 | https://www.reuters.com/business/healthcare-pharmaceuticals/sandoz-launches-rival-version-abbvies-arthritis-drug-humira-2023-07-01/ | Swiss drugmaker Sandoz said on Saturday it had launched a biosimilar version of AbbVie Inc's big selling arthritis treatment Humira, adding to U.S. competition for the drug that started in January. | Sandoz launches rival version of AbbVie's arthritis drug Humira | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Market Watch | 2023-06-30 13:28:00 | https://www.marketwatch.com/story/for-abbvies-blockbuster-humira-cheaper-competitors-pose-surprisingly-little-threat-analysts-say-bf42114e | AbbVie's ABBV, +1.53% rheumatoid arthritis drug Humira, one of the top-selling biopharmaceutical products of all time, will have new lower-cost competition starting Saturday. But even as nearly identical competitors become available at big discounts to Humira's list price, they may be hard-pressed to knock the blockbus... | For AbbVie's blockbuster Humira, cheaper competitors pose surprisingly little threat, analysts say | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2023-06-30 12:39:00 | https://investorplace.com/2023/06/pharma-stocks-to-buy/ | Pharmaceutical stocks have not shared in this year's bull rally. Year to date, the S&P Pharmaceuticals Select Industry index is down 1% while the benchmark S&P 500 index has gained 15%. | The 3 Most Undervalued Pharma Stocks to Buy Now: June 2023 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2023-06-29 18:54:40 | https://www.zacks.com/commentary/2114999/3-dividend-kings-yielding-royal-sums | If you are focused on investing for income look no further. Dividend Kings are stocks that have raised their dividends for at least 50 consecutive years, a feat made possible by uber-consistent business management and commitment to shareholders. | 3 Dividend Kings Yielding Royal Sums | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Market Watch | 2023-06-29 17:38:00 | https://www.marketwatch.com/story/abbvie-president-given-added-coo-duties-b6de9e3a | AbbVie Inc. ABBV, +0.54% said late Thursday its vice chairman and president will take on the added role of chief operating officer, according to a filing with the Securities and Exchange Commission. The drug maker said it appointed Robert Michael as president and COO. | AbbVie president given added COO duties | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2023-06-29 15:35:24 | https://seekingalpha.com/article/4614459-july-dividend-kings-5-buys-4-to-watch | "There is only one-criterion to be included among the Dividend Kings: a publicly-traded company must increase its total fiscal-year dividend-payout for a minimum of 50 consecutive-years."--Dogs of the Dow. The 50 Dividend Kings screened as of June 27, 2023, represented nine of eleven Morningstar Sectors. Broker targete... | July Dividend Kings: 5 Buys, 4 To Watch | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-06-29 10:00:00 | https://www.fool.com/investing/2023/06/29/5-high-yielding-dividend-stocks-that-are-bargain/ | Some of the biggest names in healthcare are on sale right now. J&J, AbbVie, Bristol Myers, Amgen, and Pfizer all trade at low valuations. | 5 High-Yielding Dividend Stocks That Are Bargain Buys | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-06-28 08:30:00 | https://www.fool.com/investing/2023/06/28/what-will-abbvie-buy-next/ | AbbVie may be an active player on the merger and acquisition scene in 2023. Blueprint Medicines and Krystal Biotech are two budget-friendly targets. | What Will AbbVie Buy Next? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2023-06-27 20:52:35 | https://investorplace.com/2023/06/7-stocks-that-every-40-year-old-should-buy-today/ | While swinging for the fences brings excitement to the art of investing, slow and steady usually wins the race, which brings us to the best investments for 40-year-olds. Around this time frame, the emphasis centers on balance. | 7 Stocks That Every 40-Year-Old Should Buy Today | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2023-06-26 12:46:38 | https://www.zacks.com/stock/news/2113181/abbvie-abbv-gets-chmp-positive-opinion-for-atogepant-approval | AbbVie (ABBV) receives a positive recommendation from the European Union's medicinal products committee for the approval of its migraine treatment candidate, atogepant. | AbbVie (ABBV) Gets CHMP Positive Opinion for Atogepant Approval | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-06-25 05:55:00 | https://www.fool.com/investing/2023/06/25/1-phenomenal-high-yield-dividend-stock-you-can-buy/ | This stock is a Dividend King with a juicy dividend yield. It faces some near-term headwinds, but they should only be temporary. | 1 Phenomenal High-Yield Dividend Stock You Can Buy and Hold Forever | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2023-06-22 10:21:22 | https://www.zacks.com/stock/news/2111711/investors-heavily-search-abbvie-inc-abbv-here-is-what-you-need-to-know | AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock. | Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-06-22 08:00:00 | https://www.fool.com/investing/2023/06/22/2-no-brainer-healthcare-stocks-to-buy-right-now/ | AbbVie's shares are dropping due to an anticipated obstacle, but the company's prospects remain bright. Veeva Systems' deep moat and excellent growth prospects make it a solid stock to buy today. | 2 No-Brainer Healthcare Stocks to Buy Right Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2023-06-21 07:15:00 | https://seekingalpha.com/article/4612572-2-buffett-style-blue-chip-buys-for-whats-coming-next | The market rally is unjustified by deteriorating economic fundamentals and $300 billion per month in reverse money printing. A recession is still likely, and current earnings expectations are wildly optimistic. A 20% to 35% market correction within 9 months is likely. Smart investors know that hiding under the bed isn'... | 2 Buffett-Style Blue-Chip Buys For What's Coming Next | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2023-06-20 14:40:09 | https://investorplace.com/2023/06/ready-for-a-rebound-7-blue-chips-set-to-regain-their-market-mojo/ | While the smaller-capitalization trades tend to attract the most speculative attention, for reliable upside prospects, investors may want to consider blue-chip stocks to buy. To better understand the motivation behind targeting these stalwarts, a baseball analogy may be helpful. | Ready for a Rebound: 7 Blue-Chips Set to Regain Their Market Mojo | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2023-06-16 09:20:39 | https://www.zacks.com/stock/news/2109293/abbvie-s-abbv-skyrizi-meets-ulcerative-colitis-study-goals | AbbVie's (ABBV) Skyrizi achieves statistical significance with its primary endpoint of clinical remission in a late-stage study as a maintenance treatment for ulcerative colitis. | AbbVie's (ABBV) Skyrizi Meets Ulcerative Colitis Study Goals | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-06-16 08:30:00 | https://www.fool.com/investing/2023/06/16/this-biotech-is-about-to-eat-abbvies-market-share/ | Coherus Biosciences will soon likely commercialize a generic copy of Humira. Humira is AbbVie's largest-grossing drug, and one of the most lucrative of all time. | This Biotech Is About to Eat AbbVie's Market Share, but Is It a Buy? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Reuters | 2023-06-16 07:28:11 | https://www.reuters.com/business/healthcare-pharmaceuticals/roches-cancer-therapy-gets-us-fda-nod-heating-up-competition-with-abbvie-2023-06-16/ | The U.S. Food and Drug Administration (FDA) greenlighted Roche Holding AG's experimental therapy to treat a type of advanced blood cancer, nearly a month after the approval of a rival therapy from AbbVie Inc. | Roche's cancer therapy gets US FDA nod, heating up competition with AbbVie | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Market Watch | 2023-06-15 08:30:00 | https://www.marketwatch.com/story/beigene-shares-drop-after-abbvie-unit-files-patent-infringement-lawsuit-over-cancer-drug-d560d07f | BeiGene Ltd.'s ADR BGNE was down more than 7% premarket on Thursday after AbbVie's ABBV Pharmacyclics unit filed a patent-infringement lawsuit against the biotech company. | BeiGene shares drop after AbbVie unit files patent-infringement lawsuit over cancer drug | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Reuters | 2023-06-15 07:10:44 | https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-coherus-agree-resolve-dispute-over-humira-biosimilar-2023-06-15/ | Coherus BioSciences Inc said on Thursday it had agreed to resolve a dispute over its plans to launch a lower-priced version of AbbVie Inc's Humira, its blockbuster rheumatoid arthritis drug. | Abbvie, Coherus agree to resolve dispute over Humira biosimilar | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
CNBC Television | 2023-06-12 14:40:20 | https://www.youtube.com/watch?v=VkhPGLoxUkk | The "Halftime Report" traders give their top picks to watch for the second half. | Final Trades: Abbvie, Broadcom, Deere | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2023-06-11 16:25:20 | https://investorplace.com/2023/06/7-top-blue-chip-stocks-to-buy-in-june-2023/ | The market probably feels like the movie Groundhog's Day for many investors. The major indexes continue to trade within a range, which is frustrating both bulls and bears. | 7 Top Blue-Chip Stocks to Buy in June 2023 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-06-10 08:05:00 | https://www.fool.com/investing/2023/06/10/better-long-term-buy-abbvie-or-novo-nordisk/ | Novo Nordisk is forecasting revenue and operating profit growth this year. AbbVie said it expects to return to revenue growth in 2025. | Better Long-Term Buy: AbbVie or Novo Nordisk? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2023-06-09 17:39:31 | https://seekingalpha.com/article/4610649-4-factor-dividend-growth-portfolio-passively-outpacing-the-market | The 4-factor dividend growth portfolio is a strategy that leverages the stock selection process of Schwab U.S. Dividend Equity ETF™, with a few minor twists. The portfolio gained 1.84% in May, outperforming the S&P 500 by 1.40%. Year-to-date the portfolio is up 6.66% and trailing the S&P 500 by 2.99%. Since inception, ... | 4 Factor Dividend Growth Portfolio - Passively Outpacing The Market | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2023-06-09 10:12:07 | https://www.zacks.com/stock/news/2106290/here-is-what-to-know-beyond-why-abbvie-inc-abbv-is-a-trending-stock | AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects. | Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Market Watch | 2023-06-09 10:09:00 | https://www.marketwatch.com/story/ny-ag-approves-17-3-billion-opioid-settlement-with-cvs-walgreens-teva-and-abbvies-allergan-c7d4ec8e | New York Attorney General Letitia James announced Friday the final approval of $17.3 billion in national settlement agreements with drug-store chains CVS Health Corp. CVS, and Walgreens Boots Alliance Inc. WBA, -0.68%, and with drug makers Teva Pharmaceutical Industries Ltd. TEVA, -0.61% and AbbVie Inc.'s ABBV, +0.61% ... | NY AG approves $17.3 billion opioid settlement with CVS, Walgreens, Teva and AbbVie's Allergan | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2023-06-08 18:59:40 | https://seekingalpha.com/article/4610412-4-dividend-aristocrat-buys-for-june-and-5-to-watch | "Dividend Aristocrats in the S&P 500 Index have raised their annual payouts every year for at least 25 consecutive years. "--Kiplinger.com/Investing. 67 Aristocrats, screened as of June 6, 2023, represented all eleven Morningstar Sectors. Broker estimated-top-ten net-gains ranged 20.58%-43.58% topped-by TGT & VFC. By y... | 4 Dividend Aristocrat Buys For June And 5 To Watch | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-06-08 12:15:00 | https://www.fool.com/investing/2023/06/08/is-abbvie-or-amgen-the-better-bargain-buy-right-no/ | Exclusivity losses can be big setbacks for pharma companies. AbbVie and Amgen both face this key overhang. | Is AbbVie or Amgen the Better Bargain Buy Right Now? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-06-06 07:30:00 | https://www.fool.com/investing/2023/06/06/300-a-month-in-these-3-stocks-could-make-you-a-mil/ | AbbVie's drug portfolio and pipeline are both exceptional. Air Products & Chemicals is a wonderful business in a pivotal industry. | $300 a Month in These 3 Stocks Could Make You a Millionaire by Retirement | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2023-06-03 07:45:00 | https://seekingalpha.com/article/4608988-10-dividend-aristocrats-for-ultimate-6-percent-yielding-retirement-portfolio | The NY Fed estimates a 68% recession probability within the next 12 months, the highest risk in 42 years. Dividend aristocrats can provide a relatively safe investment option during a recession, with a history of raising dividends through economic downturns and much lower volatility. A diversified high-yield portfolio ... | 10 Dividend Aristocrats For The Ultimate 6% Yielding Retirement Portfolio | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-06-01 16:23:28 | https://www.fool.com/investing/2023/06/01/7-best-dividend-stocks-to-buy-now-in-june-2023/ | These top dividend stocks are attractive at these levels and lower, and they add excellent diversity to a long-term investing portfolio. | 7 Best Dividend Stocks to Buy Now in June 2023 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-06-01 12:50:20 | https://www.fool.com/investing/2023/06/01/why-abbvie-and-amgen-are-moving-lower-today/ | Today, Coherus and Mark Cuban announced a partnership to launch an ultra-low-priced Humira biosimilar. This steep discount might have negative consequences for both AbbVie and Amgen later on this year. | Why AbbVie and Amgen Are Moving Lower Today | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2023-05-31 16:34:47 | https://seekingalpha.com/article/4608580-buy-7-june-dividend-kings-and-watch-3 | "There is only one-criterion to be included among the Dividend Kings: a publicly-traded company must increase its total fiscal-year dividend-payout for a minimum of 50 consecutive-years."--Dogs of the Dow. The 47 Dividend Kings screened as of May 26, 2023, represented eight of eleven Morningstar Sectors. Broker targete... | Buy 7 June Dividend Kings And Watch 3 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2023-05-29 10:05:14 | https://www.zacks.com/stock/news/2100818/abbvie-inc-abbv-is-attracting-investor-attention-here-is-what-you-should-know | AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock. | AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2023-05-26 09:00:00 | https://seekingalpha.com/article/4607475-buy-alert-3-undervalued-high-yield-gems-for-your-retirement | This article discusses three high-yielding stocks for retirees and income-oriented investors: ONEOK, AbbVie, and Realty Income. ONEOK is a cyclical income play with a 6.5% yield, AbbVie offers a high-quality healthcare yield of 4.2%, and Realty Income provides steady and reliable dividend growth with a 5.2% yield. | Buy Alert: 3 Undervalued High-Yield Gems For Your Retirement | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Forbes | 2023-05-26 07:00:56 | https://www.forbes.com/sites/greatspeculations/2023/05/26/should-you-pick-abbvie-stock-over-lly/ | Looking at stock returns, Eli Lilly has outperformed AbbVie and the broader indices. | Should You Pick AbbVie Stock Over LLY? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Kiplinger | 2023-05-25 13:26:01 | https://www.kiplinger.com/investing/best-retirement-stocks | The best retirement stocks ideally have high dividend yields that can be sustained. This can lead to steady income and long-term value for retirees. | Best Retirement Stocks to Buy Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-05-25 09:37:00 | https://www.fool.com/investing/2023/05/25/2-dividend-kingsthat-are-yielding-more-than-4/ | AbbVie's Humira now faces competition from biosimilars, but things look more promising in the long run. 3M's margins have been shrinking, but its biggest risk is the plethora of lawsuits relating to its earplugs. | 2 Dividend Kings on Sale That Are Yielding More Than 4% | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2023-05-24 08:35:38 | https://www.benzinga.com/trading-ideas/long-ideas/23/05/32550121/wall-streets-most-accurate-analysts-say-buy-these-3-health-care-stocks-with-over-3-divid?SNAPI | During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout. | Wall Street's Most Accurate Analysts Say Buy These 3 Health Care Stocks With Over 3% Dividend Yields - CVS Health (NYSE:CVS), AbbVie (NYSE:ABBV) | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2023-05-22 13:35:07 | https://www.zacks.com/stock/news/2098146/abbvie-abbv-gets-fda-nod-for-lymphoma-drug-epcoritamab | The FDA approves AbbVie's (ABBV) epcoritamab, to be marketed as Epkinly, for relapsed/refractory large B-cell lymphoma, a form of NHL. Epkinly is AbbVie's third blood cancer drug. | AbbVie (ABBV) Gets FDA Nod for Lymphoma Drug Epcoritamab | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2023-05-21 17:00:00 | https://seekingalpha.com/article/4606259-the-abbvie-update-q1-spotlight-on-life-after-humira | AbbVie stock is down 10% after Q1 earnings. The mixed-bag quarter offered clarity on the effect of Humira's lost sales, Rinvoq and Skyrizi, and other franchises. | The AbbVie Update: Q1 Spotlight On Life After Humira | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-05-20 06:14:00 | https://www.fool.com/investing/2023/05/20/3-relatively-safe-stocks-to-buy-if-a-recession-is/ | AbbVie's current headwinds are only temporary. Gilead Sciences' business remains rock-solid. | 3 Relatively Safe Stocks to Buy if a Recession Is on the Way | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-05-20 05:52:00 | https://www.fool.com/investing/2023/05/20/3-no-brainer-dividend-stocks-to-buy-with-1000-righ/ | Brookfield Renewable is poised for tremendous growth. Enterprise Products Partners' ultra-high dividend is rock-solid. | 3 No-Brainer Dividend Stocks to Buy With $1,000 Right Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2023-05-19 11:28:14 | https://www.zacks.com/stock/news/2097424/abbvie-s-abbv-rinvoq-gets-fda-nod-to-treat-crohn-s-disease | AbbVie (ABBV) announces the seventh FDA approval of its JAK inhibitor, Rinvoq, for the treatment of adults with moderately to severely active Crohn's disease. | AbbVie's (ABBV) Rinvoq Gets FDA Nod to Treat Crohn's Disease | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2023-05-18 18:00:00 | https://seekingalpha.com/article/4605415-5-stocks-with-steady-dividend-growth-attractive-valuation | I consider companies that combine a relatively high Dividend Yield and Dividend Growth Rate to be particularly attractive for dividend income investors. The reason being that these companies can help you to significantly increase your extra income in the form of dividends from year to year. | 5 High Yield Stocks With Steady Dividend Growth And An Attractive Valuation | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2023-05-16 10:39:35 | https://www.zacks.com/stock/news/2095706/abbvie-inc-abbv-is-a-trending-stock-facts-to-know-before-betting-on-it | AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock. | AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2023-05-09 06:40:15 | https://seekingalpha.com/article/4601865-abbvie-or-johnson-and-johnson-lets-ask-peter-lynch | Many investors do not consider Peter Lynch to be a dividend investor – an unfortunate misunderstanding in my view. He has so many valuable insights into dividend stocks. It is just these insights are overshadowed by his success with 10-baggers. | AbbVie Or Johnson & Johnson? Let's Ask Peter Lynch | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2023-05-08 20:17:23 | https://investorplace.com/2023/05/7-dividend-stocks-that-will-pay-you-through-any-market-turmoil/ | While there's nothing quite as exciting as betting everything on a hot growth enterprise, prudent investors may want to consider the best dividend stocks for market crash. In late April, CNBC reported that investors face the threat of persistently higher inflation while simultaneously digesting a bleak economic outlook... | 7 Dividend Stocks That Will Pay You Through Any Market Turmoil | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-05-06 09:44:00 | https://www.fool.com/investing/2023/05/06/1-relatively-safe-dividend-growth-stock-to-buy-han/ | AbbVie just reported poor earnings, and there may be regulatory headwinds coming. Despite that, things appear to be going according to management's plan. | 1 Relatively Safe Dividend Growth Stock to Buy Hand Over Fist Right Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-05-06 09:00:00 | https://www.fool.com/investing/2023/05/06/looking-for-steady-passive-income-buy-abbvie-stock/ | As expected, AbbVie's revenue and earnings both dropped in Q1. However, the drug company offers a sizable dividend that is well-covered. | Looking for Steady, Passive Income? Buy AbbVie Stock | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2023-05-04 16:41:35 | https://investorplace.com/2023/05/7-dividend-paying-large-cap-stocks-to-buy-in-may-2/ | Large-cap stocks are those that have a market capitalization above $10 billion and are synonymously known as big cap stocks. Market cap is calculated by multiplying the share price by the number of shares outstanding. | 7 Dividend-Paying Large-Cap Stocks to Buy in May | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
MarijuanaStocks | 2023-05-04 16:00:14 | https://marijuanastocks.com/top-ancillary-and-medical-marijuana-stocks-in-may-2023/ | Are These Cannabis Stocks Good Long-Term Positions? The post Top Ancillary And Medical Marijuana Stocks In May 2023 appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™. | Top Ancillary And Medical Marijuana Stocks In May 2023 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-05-03 14:00:00 | https://www.fool.com/investing/2023/05/03/2-things-about-abbvie-that-investors-are-ignoring/ | AbbVie's sales of two key immunology drugs missed some analysts' estimates -- but plenty of signs point to long-term growth. The company also is excelling in two other growth markets. | 2 Things About AbbVie That Investors Are Ignoring | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2023-05-03 07:00:00 | https://seekingalpha.com/article/4599169-abbvie-stock-sells-off-post-q1-earnings-i-am-buying | AbbVie dropped almost 8% after its most recent earnings release, which was triggered by lower-than-expected guidance and a sales decline caused by the Humira patent loss. The good news is that the company is seeing strong growth in its non-Humira core business, with accelerating growth expectations in the years ahead. | AbbVie Sells Off, I Am Buying | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2023-05-02 10:40:13 | https://www.zacks.com/stock/news/2087986/investors-heavily-search-abbvie-inc-abbv-here-is-what-you-need-to-know | AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock. | Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-05-02 09:39:48 | https://www.fool.com/investing/2023/05/02/3-of-the-best-high-yielding-dividend-stocks-to-buy/ | AbbVie, Toronto-Dominion Bank, and Verizon Communications all offer yields exceeding 3%. These businesses have strong financials that can enable them to not only continue paying their current dividends but potentially even increase them. | 3 of the Best High-Yielding Dividend Stocks to Buy in May | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-05-02 05:50:00 | https://www.fool.com/investing/2023/05/02/vertex-pharmaceuticals-stock-is-an-even-better-buy/ | AbbVie announced last week that it's shutting down its cystic fibrosis (CF) program. This decision makes Vertex's monopoly in CF even stronger. | Vertex Pharmaceuticals Stock Is an Even Better Buy Now Thanks to AbbVie | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-05-01 09:30:00 | https://www.fool.com/investing/2023/05/01/where-will-abbvie-be-in-5-years/ | AbbVie is facing Humira's loss of exclusivity, but it is working on fixing that problem. The company should earn approval for new products, thereby improving its lineup. | Where Will AbbVie Be in 5 Years? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-05-01 05:51:00 | https://www.fool.com/investing/2023/05/01/abbvie-stock-plunged-should-you-buy-the-dip/ | AbbVie's shares crashed last week after the company reported its Q1 results. The drugmaker's revenue fell due to plummeting sales of Humira and challenges for other products. | AbbVie Stock Plunged: Should You Buy the Dip? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2023-04-30 14:48:26 | https://investorplace.com/2023/04/7-high-yield-dividend-stocks-to-buy-and-hold-forever/ | The major indices have been trading in a broad range for over a year. This is frustrating for bulls and bears alike. | 7 High-Yield Dividend Stocks to Buy and Hold Forever | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-04-30 05:41:00 | https://www.fool.com/investing/2023/04/30/abbvies-blockbuster-is-falling-fast-time-to-sell/ | AbbVie stock recently dropped by about 8% in a single day after the company released a disappointing first-quarter earnings report. Humira's global sales peaked above $21 billion, but the drug lost patent-protected exclusivity in the U.S. this January. | AbbVie's Blockbuster Is Falling Fast. Time to Sell? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-04-29 06:14:00 | https://www.fool.com/investing/2023/04/29/3-unstoppable-stocks-to-buy-right-now/ | AbbVie has several blockbusters to drive growth despite facing sales declines for Humira. Pfizer has much better long-term prospects than might meet the eye. | 3 Unstoppable Stocks to Buy Right Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-04-27 14:25:48 | https://www.fool.com/investing/2023/04/27/why-abbvie-stock-is-crashing-today/ | AbbVie reported 2023 first-quarter earnings today. Hefty declines in immunology, oncology, and medical aesthetics sales sparked a sell-off in the drugmaker's stock. | Why AbbVie Stock Is Crashing Today | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-04-27 08:30:00 | https://www.fool.com/investing/2023/04/27/1-dividend-stock-to-buy-hand-over-fist-in-may-and/ | Companies that pay sustainable dividends do so with the help of steady cash flows. AbbVie's dividend is relatively sustainable, and it's also likely to keep rising. | 1 Dividend Stock to Buy Hand Over Fist in May and 1 to Avoid | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Market Watch | 2023-04-27 08:15:00 | https://www.marketwatch.com/story/abbvie-stock-falls-toward-a-6-week-low-after-adjusted-profit-fell-short-of-expectations-but-the-full-year-outlook-was-raised-103d942e | Shares of AbbVie Inc. ABBV dove 6.2% toward a six-week low in premarket trading Thursday, after the biopharmaceutical company missed first-quarter profit expectations but lifted its full-year outlook. Net income dropped to $239 million, or 13 cents a share, from $4.49 billion, or $2.51 a share, in the year-ago period. | AbbVie stock falls toward a 6-week low after adjusted profit fell short of expectations, but the full-year outlook was raised | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2023-04-26 10:40:40 | https://www.zacks.com/stock/news/2084870/drug-biotech-stocks-q1-earnings-due-apr-27-lly-abbv-more | Let's look at the five biotech/pharma companies slated to release quarterly results on Apr 27. | Drug/Biotech Stocks' Q1 Earnings Due Apr 27: LLY, ABBV & More | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-04-25 06:00:00 | https://www.fool.com/investing/2023/04/25/3-winning-stocks-to-buy-no-matter-what-the-market/ | AbbVie and Intuitive Surgical benefit from their leadership in their markets -- and ongoing demand in healthcare. Home Depot has added $40 billion in sales growth in recent years. | 3 Winning Stocks to Buy No Matter What the Market Is Doing | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-04-23 14:00:00 | https://www.fool.com/investing/2023/04/23/the-best-stocks-to-invest-20000-in-right-now/ | Investing across a few different companies could bring a lot of positive elements to your portfolio -- from dividends to growth potential. Healthcare is a great place to look for safe stocks and stocks offering high-growth opportunities. | The Best Stocks to Invest $20,000 in Right Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-04-22 07:20:00 | https://www.fool.com/investing/2023/04/22/3-top-dividend-kings-to-buy-for-the-long-haul/ | Johnson & Johnson just raised its quarterly dividend for the 61st straight year. AbbVie is counting on Skyrizi and Rinvoq and its deep pipeline to help replace lost revenue from Humira. | 3 Top Dividend Kings to Buy for the Long Haul | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2023-04-19 12:35:32 | https://seekingalpha.com/article/4595011-4-factor-dividend-growth-portfolio-sour-month | The 4-factor dividend growth portfolio was launched on November 1st, 2022, and despite a poor start to April the long term return is still attractive. The portfolio outperformed the S&P 500 Total Return by 29 bps during the month of March. | 4-Factor Dividend Growth Portfolio - Sour Month | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.